{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Pancytopenia", "query": { "condition": "Autoimmune Pancytopenia" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Pancytopenia&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T23:43:30.674Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04304820", "title": "Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Horse-Anti-thymocyte-Globulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "3 Years to 99 Years" }, "enrollment_count": 80, "start_date": "2020-05-07", "completion_date": "2033-12-18", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04304820" }, { "nct_id": "NCT07660783", "title": "Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Marrow Failure", "Hemoglobinopathies", "Primary Immune Deficiency (PID)", "Autoimmune Cytopenia", "Immune Dysregulation", "Hemophagocytic Lymphohistiocytosis (HLH)", "Non Malignant Disorders" ], "interventions": [ { "name": "ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "50 Years", "sex": "ALL", "summary": "6 Months to 50 Years" }, "enrollment_count": 40, "start_date": "2026-09", "completion_date": "2035-09", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07660783" }, { "nct_id": "NCT06056297", "title": "A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neutropenia" ], "interventions": [ { "name": "Mavorixafor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "X4 Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 176, "start_date": "2024-06-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056297" }, { "nct_id": "NCT01351545", "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancies", "Inherited Disorders of Metabolism", "Inherited Abnormalities of Platelets", "Histiocytic Disorders", "Acute Myelogenous Leukemia (AML or ANLL)", "Acute Lymphoblastic Leukemia (ALL)", "Other Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases", "Other Leukemia", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma", "Multiple Myeloma/ Plasma Cell Disorder (PCD)", "Inherited Abnormalities of Erythrocyte Differentiation or Function", "Disorders of the Immune System", "Autoimmune Diseases", "Severe Aplastic Anemia" ], "interventions": [ { "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 99999, "start_date": "2011-10", "completion_date": "2041-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351545" }, { "nct_id": "NCT01193283", "title": "Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aplastic Anemia", "Neutropenia", "Pancytopenia", "Severe Aplastic Anemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 22, "start_date": "2010-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-05-22", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193283" }, { "nct_id": "NCT00260689", "title": "Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunosuppresion", "Thrombocytopenia", "Pancytopenia", "Neutropenia" ], "interventions": [ { "name": "Anti-thymocyte globulin (rabbit)", "type": "BIOLOGICAL" }, { "name": "Anti-thymocyte globulin (horse)", "type": "BIOLOGICAL" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 136, "start_date": "2005-11-28", "completion_date": "2016-05-04", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260689" }, { "nct_id": "NCT01962415", "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Immunodeficiency (PID)", "Congenital Bone Marrow Failure Syndromes", "Inherited Metabolic Disorders (IMD)", "Hereditary Anemias", "Inflammatory Conditions", "Systemic Juvenile Idiopathic Arthritis (sJIA)", "Juvenile Rheumatoid Arthritis (JRA)" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Months to 55 Years" }, "enrollment_count": 100, "start_date": "2014-02-04", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962415" }, { "nct_id": "NCT00392951", "title": "Sirolimus for Autoimmune Disease of Blood Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Autoimmune Pancytopenia", "Autoimmune Lymphoproliferative Syndrome (ALPS)", "Evans Syndrome", "Idiopathic Thrombocytopenic Purpura", "Anemia, Hemolytic, Autoimmune", "Autoimmune Neutropenia", "Lupus Erythematosus, Systemic", "Inflammatory Bowel Disease", "Rheumatoid Arthritis" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 30, "start_date": "2006-12", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392951" }, { "nct_id": "NCT01891994", "title": "Extended Dosing With Eltrombopag for Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia (SAA)" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2013-06-28", "completion_date": "2022-08-24", "has_results": true, "last_update_posted_date": "2023-04-25", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01891994" }, { "nct_id": "NCT01328587", "title": "Eltrombopag for Moderate Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate Aplastic Anemia", "Unilineage Bone Marrow Failure Disorders" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 34, "start_date": "2012-03-13", "completion_date": "2026-01-06", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-07-22T23:43:30.674Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328587" } ] }